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Breast cancer has been recognized as the leading cause of death in women worldwide. Research has shown the importance of
complementary and alternative therapies in cancer. In this study, we investigated the antitumoural therapeutic effects of Malaysian
Tualang honey (TH) and Australian/New Zealand Manuka honey (MH) against breast cancer in rats. Thirty syngeneic virgin
female Sprague-Dawley (SD) rats were induced by the carcinogen 1-methyl-1-nitrosourea (MNU) 80mg/kg. The treatment started
when first palpable tumour reached 10–12mm in size by dividing rats into following groups: Group 0 (negative control); Group
1 (positive control); and Groups 2 and 3 which received 1.0 g/kg body weight/day of TH and MH, respectively, for 120 days.
The data demonstrate that cancer masses in TH and MH treated groups showed a lower median tumour size, weight, and
multiplicity compared with the nontreated positive control (𝑝 < 0.05). Treatment also showed a dramatic slower growth rate
(up to 70.82%) compared with the nontreated control (0%) (𝑝 < 0.05). The antitumoural effect was mediated through modulation
of tumour growth, tumour grading, estrogenic activity, and haematological parameters. Our findings demonstrate that systemic
administration of TH and MH increases the susceptibility of expression of proapoptotic proteins (Apaf-1, Caspase-9, IFN-𝛾,
IFNGR1, and p53) and decreases the expression of antiapoptotic proteins (TNF-𝛼, COX-2, and Bcl-xL 1) in its mechanism of action.
This highlights a potential novel role for TH and MH in alleviating breast cancer.
1. Introduction
Breast cancer has been recognized as the second most
common cancer after lung cancer. It is considered as the fifth
most common cause of death through cancer and the leading
cause of death in women worldwide, surpassing the cervical
cancer [1]. InMalaysia, a recent report shows breast cancer as
the most frequently diagnosed cancer and the International
Agency for Research in Cancer (GLOBOCAN) estimated the
ASR (age-standardized rate) of breast cancer in Malaysia as
38.7 per 100,000, listing breast cancer at top among general
population of Malaysia [2]. Cancer-therapeutic drugs had an
obstacle of collateral damage to the normal cells and tissues
[3].The relapse after chemotherapy, second primary tumours,
and resistance to chemotherapeutic drugs have also been
reported in breast cancer patients [4].The alternative remedy
to these unavoidable side effects is the use of natural products
[5].
Honey has clinched the attention of researchers as a com-
plementary and alternative treatment in modern medicine
[5, 6]. It is mainly composed of various sugars, phenolic
acids, flavonoids, enzymes, amino acids, proteins, andmiscel-
laneous compounds [5]. It has also been reported as a natural
phytoestrogen [7]. Tualang honey (TH) is a multifloral jungle
honey. It is produced by bees “Apis dorsata” which build their
hives on Tualang trees (Koompassia excelsa) in Malaysian
tropical rainforests [8, 9]. Research has shown that TH
exhibits antimicrobial [10], wound-healing [10], antioxidant
[9, 11], anti-inflammatory [9], antidiabetic [8, 12, 13], and
anticancer effects [14]. Manuka honey (MH) unlike Tualang
honey is a monofloral honey, produced by honey bees from
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nectars ofManuka bush (Leptospermum scoparium) through-
out New Zealand and Australia [15]. Published literature on
Manuka honey indicates its numerous therapeutic properties
against several ailments [16]. Several studies reported that
honey, being rich in flavonoids and polyphenols, has antipro-
liferative and antitumoural effects in vitro and in vivo [17].
However, the mechanisms for the anticancer effects of honey
need to be fully understood.
Full blood count is a prerequisite investigation in cancer
patients and poor blood parameters affect the outcome of
malignancies and functioning of the immune system [18].
It has also been reported that prolonged exposure to serum
estradiol (E2) is an important risk factor for the promotion of
breast cancer. The level of estrogen in breast cancer patients
has been a controversy. But, a very recent study shows a
higher serum level of endogenous estrogen (E2) and estrogen
receptors (ESR1, ESR2) in breast cancer patients with worse
prognosis. Antiestrogen therapy in breast cancer patients has
been shown to be very effective in preventing the disease and
recurrence [19].
Apoptosis is recognized as the principle mechanism of
drugs therapy-induced regression in breast cancer [5]. The
expression of pro- and antiapoptotic proteins is considered as
a hallmark for prognosis of this disease, survival to death [5,
17]. Research has shown that cancer cell lines and pretreated
primary tumour samples exhibit low level of expression of
proapoptotic and higher expression of antiapoptotic proteins
of intrinsic pathway [17]. Apoptotic protease activating
factor-1 (Apaf-1), of Caspase-9 apoptotic pathway, is a
tumor suppressor gene [20]. Loss of Apaf-1 expression can
aid tumour cells in evading immune attack-induced death
and/or Caspase-9 mediated apoptosis, resulting in metastasis
[20]. Research has suggested that interferon gamma (IFN-
𝛾), an immune potentiating agent, favours activation of
mitochondrial-operated apoptotic pathway in breast cancer
cell lines by interacting with its receptor, interferon gamma
receptor 1 (IFNGR1) [21]. Similarly, the crucial role of p53 as
amediator and cytokine of stress and apoptosis in various cell
types has been demonstrated. Its contribution to breast can-
cer remains unclear. It exhibits tumour suppression as well as
an oncogenic action [22].The higher expression of cytokines,
tumour necrosis factor alpha (TNF-𝛼), cyclooxygenase-2
(COX-2), andB-cell lymphoma extra large (Bcl-xL) in inflam-
matory breast carcinoma was found to be associated with
increasing tumour grade and the metastatic behavior of
breast carcinomas [23–25].
An investigation on the effects of honey on haematolog-
ical parameters and cytokines or markers of estrogenic as
well as apoptoticmediated pathways has not been undertaken
well.The potential “therapeutic” effects of TH andMH in our
study were to investigate the antitumoural effects, the histo-
logical features, and the tumour grades evaluation.This study
also highlights a potential therapeutic role of TH and MH to
modulate haematological parameters and the expression of
Apaf-1, Caspase-9, IFN-𝛾, IFNGR1, p53, E2, ESR1, TNF-𝛼,
COX-2, and Bcl-xL in in vivo breast cancer model. To our
knowledge, this is the first study to report the modification of
haematological parameters and estrogenic activity by admin-
istering honey as a potential therapeutic measure in in vivo
breast cancer model.
2. Materials and Methods
2.1. Animals. The experimental protocol used in this study
was approved by the animal ethics committee of Universiti
SainsMalaysia,Malaysia [USM/Animal Ethics Approval/2011/
(68) (306)]. Sprague-Dawley (SD) female rats aged between
28 and 33 days were obtained from Animal Research and
Service Centre (ARASC), Universiti Sains Malaysia (USM).
2.2. Source of Honey. Tualang honey was supplied by Fed-
eral Agricultural Marketing Authority (FAMA), Ministry of
Agriculture and Agrobased Industry, Malaysia. The honey
samples were filtrated, evaporated at 40∘C (to achieve 20%
water content), and were subjected to gamma irradiation at
25 kGy for sterilization by STERILE GAMMA, Selangor,
Malaysia. Manuka honey was purchased from the market
(packed under license number 1003 for Vitaco Health (NZ)
Ltd., New Zealand and imported and distributed by Cambert
(M) Sdn.Bhd, Malaysia).
2.3. Study Design. For tumour induction, the carcinogen
MNU(Catalog numberN1517-1G, Sigma,USA)was dissolved
in 0.9% NaCl solution acidified to pH = 5.0 with 0.05% acetic
acid by gentle heating up with hot tap water accompanied
by vigorous shaking [26]. This model was developed as
described by [26]. MNUwas injected intraperitoneally as per
80mg/kg body weight of the rats at the age of 40 days. A total
of 40 female SD rats were divided into 4 groups with 10 ani-
mals in each group.These rats were housed in a standard cage
with commercial pine chip bedding in a well ventilated ani-
mal roomwith a 12 h day/night cycle, maintained on standard
and balanced rat feed diet, and had free access to water
ad libitum. The rats were acclimatized to the animal room
conditions for at least one week prior to the experimentation.
Honey treatment by oral feeding was started when first
palpable tumour reached 10–12mm in size.The treatmentwas
planned to be continued till day 120th. The grouping of the
rats was as follows:
(a) Group 0: negative control; no tumour induction and
no honey treatment (normal rats)
(b) Group 1: positive control; rats bearing breast cancer,
but no honey treatment
(c) Group 2: breast cancer bearing rats treated with TH
1.0 g/kg body weight/day
(d) Group 3: breast cancer bearing rats treated with MH
1.0 g/kg body weight/day
The rat breast tissue areas were palpated twice weekly to
detect the appearance of cancer masses and to monitor their
progression. The number, size, and positions of the tumours
were recorded on palpation. Tumours were measured in
length and width weekly to calculate the size. The tumor size
progression (tumour size = 1/2 (length ×width2)) and assess-
ment of reduction in size were measured as described previ-
ously [27]. On 120th day of treatment, the rats were sacrificed
after i.p injection of pentobarbital 100mg/kg body weight.
The blood samples were collected by cardiac puncture and
placed in plain tubes. Blood samples were left to clot for
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2 hours prior to centrifugation for 15 minutes at 4000 rpm.
Approximately 3ml of serum was collected and stored at
−80∘C until assayed. Tumor masses were examined in vivo
then excised. Each cancer mass was fixed in neutral buffered
formalin for histological and immunohistochemical analysis.
2.4. Determination of Full Blood Count (FBC). FBC was
carried out using an automated cell count analyzer (Sysmex
KX-21, Japan) by noncyanide haemoglobin analysis. Autoan-
alyzer was capable to run several parameters for each sample
such as haemoglobin concentration, packed cell volume, red
blood cell, mean cell volume,mean corpuscular haemoglobin
concentration, mean corpuscular haemoglobin, and platelet
and white blood cell counts. The equipment sampling probe
aspirated 20 𝜇l well mixed blood samples and the result of
analysis was obtained accordingly. A total of 8-9 samples were
run for FBC for each group.
2.5. Histopathological Examination of the Breast Cancer
Masses. A total of 103H&E breast cancermasses were exam-
ined and graded, forty-seven masses from positive control
group, twenty-three of 1.0 g/kg TH, and thirty-three from
1.0 g/kg MH. The hematoxylin and eosin stained sections
were examined under light microscope at 100x, 200x, and
400xmagnification usingOlympus BX41microscope (Olym-
pus Optical Co., Ltd., Tokyo, Japan). The stained sections
were examined for grading and histological features by a
pathologist who was blind to the treatment and control. The
cancer masses were graded as per human cancers grading
system using the modified Bloom and Richardson method as
described by [28].
2.6. Determination of Apaf-1, IFN-𝛾, TNF-𝛼, and E2 at
Serum Level. Seven to eight serum samples per treatment
and control groups were analyzed to determine the level of
Apaf-1, IFN-𝛾, TNF-𝛼, and E2 in 50 𝜇l serum using Apaf-
1, IFN-𝛾, TNF-𝛼, and E2 ELISA kits (Catalog number BG-
RAT10190, Inc., Novatein Biosciences; CSB-E04579r; CSB-
E11987r and CSB-E05110r Inc., COSMO BIO, USA, resp.).
Standards included serum of known concentrations of Apaf-
1, IFN-𝛾, TNF-𝛼, and E2 and a serum blank. The ELISA
procedure was performed according to the manufacturer’s
instructions. The results were obtained by calculating the
mean absorbance at 450 nm (Spectrophotometer, Thermo
Fisher Scientific Inc., Waltham, MA, USA) for each of the
duplicate standards, controls, and samples as stated by the
manufacturer. A standard curve was created by plotting with
the absorbance value as the dependent variable (𝑌-axis) and
concentration as the independent variable (𝑋-axis); results
in an equation formatted are as follows: 𝑦 = 𝑎𝑥2 + 𝑏𝑥 + 𝑐,
with best-fit straight line, where solving for 𝑥 determined the
protein concentration of the sample.
2.7. Immunohistochemical Analysis for Apaf-1, Caspase-9, p53,
FASLG, FADD, IFNGR1, TNF-𝛼, COX-2, ESR1, and Bcl-xl
in Breast Cancer Masses. A total of 93 cancer tissues, forty
from positive control group, twenty-three from 1.0 g/kg TH,
and thirty from 1.0 g/kg MH, were immunohistochemically
stained for the marker Apaf-1 with mouse monoclonal Anti-
Rat Apaf-1 Antigen (Catalog number SC-65891, Inc., Santa
Cruz Biotechnology, USA; diluted at 1 : 100), Caspase-9 Rab-
bit polyclonal Anti-Rat Caspase-9 Antigen (Catalog number
GTX73093, Inc., GeneTex,USA; diluted at 1 : 25), FASLGwith
monoclonal mouse Anti-Rat FASLG Antigen (Catalog num-
ber PAB 8018, Inc., Abnova, Taiwan; diluted at 1 : 200), FADD
with Rabbit polyclonal Anti-Rat FADD Antigen (Catalog
number GTX73104, Inc., GeneTex, USA; diluted at 1 : 25), p53
withmonoclonalmouseAnti-Rat p53Antigen (Catalog num-
ber PAB 1801, Inc., Abcam,UK; diluted at 1 : 50), IFNGR1with
Rabbit polyclonal Anti-Rat IFNGR1 Antigen (Catalog num-
ber GTX60200, Inc., GeneTex, USA; diluted at 1 : 200), TNF-
𝛼 with polyclonal Rabbit Anti-Rat TNF-𝛼 Antigen (Catalog
number GTX74120, Inc., GeneTex, USA; diluted at 1 : 600),
ESR1 with polyclonal Rabbit Anti-Rat ESR1 Antigen (Catalog
number PAB 18170, Inc., Abnova, Taiwan; diluted at 1 : 100),
COX-2 with polyclonal Rabbit Anti-Rat COXAntigen (Cata-
log number RB-9072-R7, Inc., Labvision, USA; ready to use),
and Bcl-xL with mouse monoclonal Anti-Rat Bcl-xL Antigen
(Catalog nunberMS-1334-P1, Inc., Labvision, USA; diluted at
1 : 100). A semiquantitative scoring system developed previ-
ously [29] was used to assess the expression of proteins men-
tioned. The positive stained cells were counted in 10 fields by
first author and confirmed by pathologist (NHO) in a blinded
manner. The data was presented as a percentage of positivity.
2.8. Statistical Analyses. Data were analyzed using IBM SPSS,
Statistics version 22. Fisher Exact test was used to analyze
the tumour incidence, latency, and grading. Comparisons
between mean values of control and treatment groups were
analyzed using one-way ANNOVA with post hoc test of
Tukey’s Honest Significance Differences (Tukey’s HSD). A
mixed model two-way repeated measures ANOVA was con-
ducted to evaluate the effect of treatments on rats body
weight gain and tumour measurements.The time main effect
and the experimental groups × time interaction effect were
tested using the multivariate criterion of Wilk’s lambda (Λ).
Comparison of the median values between groups was done
by Kruskal-Wallis𝐻 test followed by Bonferroni’s correction.
𝑝 value < 0.05 was considered statistically significant.
3. Results
3.1. MNU Induction and Its Toxicity. The palpable tumours
were seen in experimental Sprague-Dawley rats in all induced
groups during postadministration of MNU at dose 80mg/kg
of body weight. Four rats died after 5–7 weeks of post-MNU-
inductionwithout apparent sign of toxicity andwere replaced
to compensate the sample size.
3.2. Tumour Multiplicity and % Reduction in Size of Primary
Tumours. At the end of study, the rats in positive control
which received no honey treatment (Group 1) had the highest
median number of tumours (tumour multiplicity) compared
with the groups treated with TH and MH (Groups 2 and
3) (𝑝 > 0.05). The used strengths of TH and MH (Groups
2 and 3) showed a significant % reduction (in size of first
three primary tumours developed) and least tumour size and
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Table 1: Tumour multiplicity, % reduction, size, and weight in TH and MH treated groups compared with the nontreated control.
Tumor
Groups
𝑝 value1
+ive control
2
(1.0 g/kg TH)
3
(1.0 g/kg MH)
∗Multiplicity 5 (4) 3 (5.25) 3 (3.5) 0.462
∗% reduction 0 (0) 70.82 (22.94) 57 (32.94) 0.000
∗Size (cm3) 1.23 (2.49) 0.17 (0.29) 0.44 (1.11) 0.000
∗Weight (g) 2.55 (7.76) 0.89 (2.62) 1.8 (3.70) 0.011
∗Kruskal-Wallis test. Data are expressed asmedian interquartile range (IqR). Values are statistically significant when 𝑝 ≤ 0.05. Multiplicity: number of tumours
developed,% reduction: the percentage reduction in size of primary tumours, TH: Tualang honey, MH: Manuka honey, and +ive control: group bearing breast
cancer but with no honey treatment.
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Figure 1: The progression of tumor size (cm3) in TH and MH
treated groups compared with the nontreated positive control. Data
is presented as mean ± SEM. A mixed model two-way repeated
measures ANOVA (𝑝 < 0.05 in all weeks). TH: Tualang honey, MH:
Manuka honey, and +ive control: group bearing breast cancer but
received no honey treatment.
weight comparedwith the nontreated positive control (Group
1). A significant statistical difference was observed between
all groups (𝑝 < 0.05). The difference between all treatment
groups among themselves was not significant (𝑝 > 0.05)
(Table 1). TH and MH dosages showed comparable results
for tumourmultiplicity, but TH showed a higher % reduction
in size of primary tumours than MH. TH presented a lower
tumour size and weight when compared with MH (Table 1).
3.3. Tumour Progression. The size of the tumours measured
weekly showed that the tumours in treated groups (Groups
2 and 3) had a slower size increment with a lesser median
tumour size of less than ≤3 and ≤2.96 cm3 for TH and MH,
respectively, during the whole experimental period of 16
weeks. Tumours in the control group showed a rapid pro-
gression over period of time reaching up to 3.84 cm3 in size.
The statistical difference was not significant for the tumour
size progression between treatment groups and control (𝑝 >
0.05); however, a significant difference was observed only
in the last few weeks (𝑝 < 0.05) (Figure 1). The difference
of tumour progression between all treatment groups among
themselves was not statistically significant (𝑝 > 0.05). Few of
the cancermasses in TH treated groups had regressed to non-
palpable state during the experimental period. TH showed a
slower tumour progression compared with MH (Figure 1).
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Figure 2: Body weight progression among all groups of rats. Data
is presented as mean ± SEM and a mixed model two-way repeated
measures ANOVA was conducted to analyze the results. A positive
body weight progression was observed over time (𝑝 > 0.05). BW:
body weight, ABW: actual body weight, TH: Tualang honey, MH:
Manuka honey, −ive control: normal rats, and +ive control: group
bearing breast cancer but received no honey treatment.
3.4. Body Weights. In general, body weights of the rats in all
groups (treated groups & nontreated control groups) gradu-
ally increased throughout the experimental period over time
(Figure 2). Data formedian bodyweights of rats in each group
is presented in Table 2. At week 16, all the rats in TH andMH
treated groups showed a higher BW change% compared with
the negative and positive controls. The difference in percent-
age body weight change (BW change%) between all groups
was found statistically not significant (𝑝 > 0.05) (Table 2).
Further analysis on the weight gain was performed by
evaluating the actual body weights of rats at week 16 by
subtracting the total tumour weight from the body weight
of the rats obtained at week 16. The difference in median
actual body weight (ABW) of treated groups compared with
negative and positive control groups was also not significant
(𝑝 > 0.05). The rats in TH and MH treated groups presented
a higher median actual body weight compared with the
rats of nontreated positive control. The rats in TH and MH
treated groups also presented a significant higher percentage
of change in actual body weight gain (ABW change%) than
the rats in nontreated positive control.Thedifference between
all treatment groups among themselves was not statistically
significant (𝑝 > 0.05). Overall, treatment with TH and
MH showed a positive effect on actual body weight gain
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Table 2: Body weight measurements of rats among all groups at week 1 and week 16.
Body weight
Groups
𝑝 valuea0
−ive control
1
+ive control
2
(1.0 g/kg TH)
3
(1.0 g/kg MH)
BW at week 1 167.5 (32.25) 191.5 (94.5) 138 (60.25) 142 (53.25) 0.300
BW at week 16 272 (32.25) 270.5 (31) 238 (55.75) 268 (31.75) 0.392
BW change (%) 66.54 (37.16) 32.14 (90.05) 68.21 (18.42) 109 (56.22) 0.182
ABW at week 16 272 (37.25) 245.49 (17.05) 236.76 (32.21) 249 (39.11) 0.07
ABW change (%) 66.54 (37.16) 26.52 (64.48) 66.89 (23.88) 78.09 (48.02) 0.110
aKruskal-Wallis test. Data are expressed as median interquartile range (IqR). Values are statistically significant when 𝑝 ≤ 0.05. Percentage body weight change
or gain (BW change%) = [(FBW − IBW) × 100]/IBW.
Actual body weight = Body weight at week 16 − weight of tumours.
Percentage actual body weight change or gain (ABW change%) = [(ABW − IBW) × 100]/IBW.
BW: body weight, FBW = final body weight, IBW: initial body weight, and ABW: actual body weight.
Table 3: Grading of tumours in groups treated with TH and MH
compared with the tumours of nontreated control.
Tumor
Groups
1
+ive control
2
(1.0 g/kg TH)
3
(1.0 g/kg MH)
Total number 47 23 33
∗Grade I (%) 6 (12.76) 14 (60.86) 22 (66.66)
∗Grade II (%) 15 (31.91) 5 (21.73) 9 (27.27)
∗Grade III (%) 26 (55.31) 4 (17.39) 2 (6.06)
∗Fisher Exact test: statistically significant difference between the groups,
𝑝 < 0.05. TH: Tualang honey; MH: Manuka honey, and +ive control: group
bearing breast cancer but received no honey treatment.
(after subtraction of tumours weight) compared with the
nontreated positive control. MH presented a higher actual
body weight gain than a similar dose of TH (Table 2).
3.5. Macroscopic Evaluation of the Tumours. The tumour
masses in the nontreated control (Group 1) were found solid,
larger in size, and hard in consistency, exhibiting areas of
necrosis and hemorrhage. Some of these tumours exhibited
pus-likematerial (necrotic tissue), exuding from the tumours
when sectioned. TH and MH treated groups (Groups 2 and
3) had tumours which were softer, paler, and smaller in size.
Table 4 shows the effect of TH and MH treatment on gross
appearance, size, and texture of tumours compared with the
nontreated control.
3.6. Tumour Grading and Histological Features. This was
concluded from the grading results that the majority of the
tumour specimens in the control group showed patterns of
grade III compared with the groups treated with TH andMH
(Groups 2 and 3)which exhibit tumoursmainly of grade I and
II. Data of the histological grading for the cancer specimens
are presented in Table 3. In all groups, the majority of the
tumours were found to be adenocarcinomas. Tumours in the
control groupwere observed to have increased heterogeneous
nuclei formation, which were hyperchromatic, vesicular, and
highly pleomorphic, with moderate cytoplasm and increased
mitotic activity compared with TH and MH treated groups
which had fatty tissue with small nucleus and cystic spaces
(Table 4). TH treated groups presented a higher percentage
of grade I tumours compared with those treated with MH.
Major types of carcinoma identified in all groupswere benign,
DCIS (ductal carcinoma in situ), micropapillary, and NOS
(not-otherwise specified) (Table 6). The majority of the
specimens in the positive control group showedNOS types of
carcinoma (40/49, 81.63%), followed bymicropapillary (4/49,
8.16%), DCIS (3/49, 6.12%), and benign (2/49, 4.08%). In
group treated with 1.0 g/kg TH, 48.38% carcinomas (15/31)
were of types NOS followed by benign (8/31, 25.80%) and
micropapillary (8/31, 25.80%) types. The group treated with
MH 1.0 g/kg had NOS (25/35, 71.42%) as the major type of
carcinoma followed by micropapillary (8/35, 22.85%) and
benign (2/35, 5.71%) (Table 5). The percentage of benign
patterns was found higher in TH and MH treated groups
compared with the nontreated control. In summary, the
cancers which developed in TH and MH treated groups
had less aggressive tumours behavior compared with cancers
developed in nontreated control.
3.7. Haematological Parameters. The results of haematolog-
ical parameters of negative control were used to establish
a normal or standard reference range. Treatment with TH
and MH showed a potentiating effect on Hb, RBC, PCV,
lymphocytes, and eosinophils compared with the nontreated
positive control, while, these honeys showed a lowering effect
on polymorphs andmonocytes. It was also observed thatMH
showed a slightly potentiating effect, and TH showed a lower-
ing effect onTWBCwhen comparedwith the nontreated pos-
itive control. MH demonstrated a slightly potentiating effect
on MCV compared with the nontreated positive control.
However, TH showed no significant potentiating or lowering
effect on MCV compared with the nonpositive control. It
was found that the level of MCH and MCHC was almost
comparable for TH and MH compared with the nontreated
positive control. The results for RDW showed that TH and
MH treatments showed a slightly lowering effect on RDW
compared with the nontreated positive control. Treatment
with TH showed a potentiating effect on platelets count,
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Table 4: The gross morphology and histology of the breast tumours of rats in TH and MH treated groups compared with the nontreated
positive control. The H & E stained sections examined under light microscopy at ×400 magnification.Themajority of tumours in nontreated
control group were of grade III with increased heterogeneous nuclei formation and mitotic activity (plate (a), arrow) compared with the
tumours in TH and MH treatment groups which were of grade I and II (less aggressive) (B): (a) = +ive control, (b) = 1.0 g/kg TH, and (c) =
1.0 g/kg MH. TH: Tualang honey, MH: Manuka honey, and +ive control: group bearing breast cancer but received no honey treatment.
Study groups→ Group 1+ive control
Group 2
1.0 g/kg TH
Group 3
1.0 g/kg MH
(A)The gross
appearance of
tumours
(a) (b) (c)
(B) The
histology of the
breast cancer
(a) (b) (c)
Table 5: The % age of histological patterns identified in TH and MH treated groups versus nontreated positive control.
Group Total Number of tumours (amount%)
Benign DCIS Micropapillary NOS
1
+ive control 49 2 (4.08) 3 (6.12) 4 (8.16) 40 (81.63)
2
(1.0 g/kg TH) 31 8 (25.80) 0 (0) 8 (25.80) 15 (48.38)
3
(1.0 g/kg MH) 35 2 (5.71) 0 8 (22.85) 25 (71.42)
TH: Tualang honey, MH: Manuka honey, DCIS: ductal carcinoma in situ, NOS: not-otherwise specified, and +ive control: group bearing breast cancer but
received no honey treatment.
while, MH presented a lowering effect compared with the
nontreated positive control.The difference for potentiating or
lowering effect on different parameters was minute between
TH and MH themselves. The detailed results with statistical
analyses are presented in Table 7.
3.8. Determination of Serum Level Concentration of Apaf-1,
IFN-𝛾, TNF-𝛼, and E2. Serum levels of Apaf-1, IFN-𝛾, TNF-
𝛼, and E2 in the negative control group (Group 0) were used
to establish a normal reference range. The rats treated with
TH and MH (Groups 2 and 3) showed a higher median
concentration of Apaf-1 and IFN-𝛾 but a lower TNF-𝛼 and
E2 concentration compared with the those of nontreated
positive control (Figure 3). A significant statistical difference
was observed between all groups (𝑝 < 0.05). The difference
between all treatment groups among themselves was not
significant (𝑝 > 0.05). TH presented a slightly higher
Apaf-1 concentration and comparable results for IFN-𝛾when
compared to a similar dose of MH. TH showed a lower
E2 concentration and a slightly higher TNF-𝛼 concentration
compared to MH (Figure 3).
3.9. Expression of Apaf-1, Caspase-9, p53, FASLG, FADD,
IFNGR, ESR1, COX-2, Bcl-xL, and TNF-𝛼 in Tumour Speci-
mens. The tumour specimens of TH and MH treated groups
showed a higher % expression or positivity of Apaf-1,
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Table 6: The histological patterns of tumours identified in breast cancer bearing rats among all groups. Cancers which developed in honey
treated rats had less aggressive tumours behavior with more benign pattern compared with cancers developed in nontreated control; (a)
benign, (b) DCIS, (c) micropapillary, and (d) NOS. DCIS: ductal carcinoma in situ and NOS: not-otherwise specified.
Magnification Benign DCIS Micropapillary NOS
×200
(a) (b) (c) (d)
×400
(a) (b) (c) (d)
Table 7: The haematological parameters of TH and MH treated groups compared with negative and positive controls.
Groups
𝑝 valuea1
−ive control
2
+ive control
3
(1.0 g/kg TH)
4
(1.0 g/kg MH)
RBC (1012/L) 7.35 (0.42) 5.1 (0.9) 6.8 (3.32) 6.15 (2.75) 0.003
Hb (g/dl) 15.2 (0.77) 11.35 (1.42) 13.85 (5.95) 13.85 (4.45) 0.003
PCV (%) 46 (3.25) 35 (8.25) 42.5 (17.75) 43.5 (12.25) 0.009
MCV (fl) 68.5 (3.25) 65 (4.75) 65 (11.75) 67 (10.25) 0.013
MCH (pg) 20.5 (1) 21 (2) 21 (3) 21 (3.5) 0.169
MCHC (g/L) 32 (1) 31.5 (2.25) 32 (3.5) 31.5 (2.25) 0.062
RDW (%) 11.9 (1.57) 13.95 (1.72) 12.25 (2.17) 12.65 (2.1) 0.01
TWBC (109/L) 4.75 (1.75) 6.4 (7.52) 4.82 (8.75) 7.35 (6.85) 0.02
Polymorphs (%) 32 (8.75) 46.5 (18) 31.5 (11.25) 31.5 (9.5) 0.01
Lymphocytes (%) 68 (8) 49 (19.25) 69 (9.75) 67.5 (4.5) 0.014
Monocytes (%) 2 (1.5) 2.5 (3.5) 0.5 (1) 1 (4.25) 0.231
Eosinophils (%) 0 (1) 0 (1.25) 0.5 (1) 1 (0.25) 0.102
Basophils (%) 0 0 0 0 1
Platelets’ (109/L) 839 (225.75) 627.5 (196.75) 666.5 (229.25) 540.5 (324.75) 0.01
aKruskal-Wallis test. Data are expressed as median interquartile range (IqR). Values are statistically significant when 𝑝 ≤ 0.05. FBC: full blood count, RBC: red
blood cells, Hb: haemoglobin, PCV: packed cell volume, MCV: mean corpuscular volume, MCH: mean corpuscular haemoglobin, MCHC: mean corpuscular
haemoglobin concentration, RDW: red cell distribution width, TH: Tualang honey, MH: Manuka honey, −ive control: normal rats, and +ive control: group
bearing breast cancer but received no honey treatment.
Caspase-9, p53, and IFNGR1 yet a lower% expression of ESR1,
COX-2, Bcl-xL, and TNF-𝛼 compared to those of control
(Table 8). A higher percentage of immunopositive cells was
also observed in TH and MH treated tumours compared to
the tumours of nontreated control (Tables 9 and 10). A sig-
nificant statistical difference was observed between different
groups (𝑝 < 0.05). The difference between all treatment
groups among themselves was not significant (𝑝 > 0.05). TH
showed a slightly higher % expression of Apaf-1 and a lower
expression of p53 and IFNGR1 compared to a similar dose
of MH. TH and MH showed almost comparable results for
the % expression of Caspase-9. While comparing with MH,
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Figure 3: The serum level concentration of Apaf-1 (ng/ml), IFN-𝛾 (pg/ml), TNF-𝛼 (pg/ml), and E2 (pg/ml) in the rats of TH and MH
treated groups compared to the rats of negative and positive controls. Group 0: negative control (normal rats), Group 1: positive control,
Group 2: 1.0 g/kg TH, and Group 3: 1.0 g/kg MH. Data are expressed as median interquartile range (IqR) using Kruskal-Wallis test. Values
are statistically significant, 𝑝 < 0.05. Apaf-1: apoptotic protease activating factor 1, IFN-𝛾: interferon gamma, TNF-𝛼: tumour necrosis factor
alpha, E2: estradiol, TH: Tualang honey, and MH: Manuka honey.
TH showed a slightly higher % expression of ESR1, COX-
2, and Bcl-xL and comparable results for TNF-𝛼 (Table 8).
Tumours treated with TH and MH showed no expression
of FASLG and FADD (0% expression or positivity). A very
minute expression of these proteins was observed in tumour
specimens of nontreated positive control (Tables 8 and 9).
4. Discussion
Chemotherapy is one of the most commonly used treatment
modalities against cancer. A major concern for anticancer
chemotherapeutic drugs is their potential toxicity [3]. The
existing therapeutic drugs can be complemented by alter-
native medicine [5]. Published data show that honey has
antitumour [17], antiproliferative [17], antineoplastic [30],
and antimutagenic [31] effects.Malaysian TH andAustralian/
New ZealandMHhave been shown to have anticancer effects
[14, 17]. Our study demonstrates some novel mechanistic
findings regarding the utility of TH and MH as potential
therapeutic agents against breast cancer. Our study showed
that the treatment using the same strengths of TH and MH
as a therapy was highly effective to reduce the size of primary
tumours.The rats that received TH andMH showed a slower
tumour progression and lower multiplicity, size, and weight
compared with those of nontreated positive control (Table 1).
Such changeswere also confirmed on grossmacroscopic eval-
uation (Table 4). Treatment with TH and MH seems to be
capable of reversing the tumourigenesis, which is evident by
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Table 8: The immunohistochemical expression of pro- and antiapoptotic proteins in tumours treated with TH and MH compared with the
tumours of nontreated control.
Tumors
Groups
1
+ive control
2
(1.0 g/kg TH)
3
(2.0 g/kg MH)
Total number 40 23 30
Number of Caspase-9 positive tumors (% expression) 12 (30) 16 (69.56) 21 (70)
Number of Apaf-1 positive tumors (% expression) 15 (37.5) 15 (65.21) 19 (63.33)
Number of p53 positive tumors (% expression) 17 (42.5) 14 (60.86) 20 (66.66)
Number of FASLG positive tumors (% expression) 15 (37.5) 0 0
Number of FADD positive tumors (% expression) 13 (32.5) 0 0
Number of IFNGR1 positive tumors (% expression) 20 (50) 17 (73.91) 25 (83.33)
Number of TNF-𝛼 positive tumors (% expression) 30 (75) 17 (73.91) 22 (73.33)
Number of COX-2 positive tumors (% expression) 26 (65) 11 (47.82) 13 (43.33)
Number of ESR1 positive tumors (% expression) 32 (80) 14 (60.86) 17 (56.66)
Number of Bcl-xL positive tumors (% expression) 31 (77.5) 11 (47.82) 13 (43.33)
Kruskal-Wallis test; statistically significant differences between the groups, 𝑝 < 0.05.
FASLG: fas ligand, FADD: fas-associated via death domain, IFNGR1: interferon gamma receptor 1, TNF-𝛼: tumour necrosis factor alpha, COX-2:
cyclooxygenase-2, ESR1: estrogen receptor 1, Bcl-xL: B-cell lymphoma extra large, +ive control: group bearing breast cancer but received no treatment, TH:
Tualang honey, and MH: Manuka honey.
the reduction in tumour size and weight in treated groups.
This modulatory effect of TH and MH on tumour pro-
gression, multiplicity, size, and weight could be attributed
to strong antioxidant [9] and antimutagenic [31] activity of
honey. Carcinogenesis is amultistep process. It can be divided
into threemain stages, initiation, promotion, and progression
[32]. Cancer-therapeutic agents may act as antipromoting
agents via intervening at initiation or promotion stages of
carcinogenesis [32]. Thus, we can assume that TH and MH
may intervene at the initiation or promotion stage to inhibit
tumour progression. This is the reason that the tumours
treated with honey appeared smaller in our study. The lower
tumour multiplicity shows that TH and MH act as antimeta-
static agent. Some of the breast lesions in our study were
found to be completely vanished at the end of the study. It has
been demonstrated that tumours can be eliminated or dimin-
ished by chronic administration of low doses of chemothera-
peutic drugs [33]. It can be hypothesized that TH and MH
treatments behaved similarly. A study byKadir and colleagues
reported that honey may modulate tumour multiplicity,
size, weight, and progression [30]. That study examined the
cancer-preventive effects of TH using a different carcinogen
DMBA (7,12-dimethylbenzanthracene), while we conducted
a cancer-therapeutic study using the carcinogenMNUwhich
has several advantages of organ specificity and tumours of
ductal origin compared to DMBA [26]. Another study has
also shown antitumoural effects of honey in animal models
[34]. It has been reported that polyphenols, phenolic acids,
and flavonoids are solely responsible for the antitumoural
effects of honey [35]. The prominent profile of these com-
pounds includes benzoic acid, gallic acid, syringic acid, p-
coumaric acid, hyacinthin, trans-cinnamic acid, caffeic acid,
salicylic acid, 3-phenyllactic acid, 3,5-dimethoxybenzoic
acid, catechin, naringenin, luteolin, apigenin, desoxyanisoin,
pinocembrin, chrysin, and tectochrysin [8]. Thus, antineo-
plastic or antitumoural effects of TH and MH may also be
attributed to these compounds.
Assessment of histological features of the cancers has piv-
otal importance for the prognosis to determine the appropri-
ate treatment [36]. Our study showed that the cancer masses
in TH treated groups were in grade I and II or less aggressive
compared with the control which had majority of grade III
(Tables 3 and 4). It was observed that the tumours in the
control group were highly pleomorphic with hyperchromatic
nuclei, moderate cytoplasm arranged in sheets or nests, and
acinar structures with increased mitotic counts. While TH
and MH treated tumours showed low to moderate nuclear
pleomorphism, fatty tissue with small lobules and moderate
cytoplasm were likely to acquire normal breast structure.
Honey is antimutagenic [31]; the better grade of the cancers in
TH treated groups is probably due to its antimutagenic effects.
Our study demonstrates that tumours of benign type were
found more frequently in treatment groups compared with
the nontreated control.Themajority of the breast tumours in
our study of MNU-induced model were invasive ductal car-
cinoma, and the commonest were of DCIS, micropapillary,
and NOS (Tables 5 and 6). Thus, TH and MH seem to act at
cellular level by reducing heterogeneous nuclei formation and
mitotic activity to improve histological grading and patterns
in tumours. This could probably lead to less aggressive types
of tumours in treated groups compared with the tumours of
nontreated control with more aggressive patterns.
The results of our study show that similar strengths of
TH and MH showed a positive effect on body weight gain
compared with the non-treated positive control (Table 2 and
Figure 2). The reason positive control rats are not gaining as
much weight as honey treated rats is perhaps due to cancer
catabolism. Cancer is a catabolic state. Thus, cancer patients
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Table 9: The immunohistochemical expression of proapoptotic proteins in TH and MH treated tumours compared with the tumours of
nontreated control; (a) +ive control for immunohistochemistry (IHC) analysis, (b) +ive control for study (group bearing breast cancer but
received no honey treatment), (c) 1.0 g/kg TH, and (d) 1.0 g/kg MH. All specimens were examined at ×400 microscopic magnification and
brown color showed antibody positivity. FASLG and FADDshowed no expression in tumours of all treatment groups, while tumours in treated
groups showed a higher expression of proapoptotic proteins than those of nontreated control. FASLG: fas ligand, FADD: fas-associated via
death domain, IFNGR1: interferon gamma receptor 1, TH: Tualang honey, and MH: Manuka honey.
Proteins +ive control(for IHC)
Group 1
+ive control
Group 2
1.0 g/kg TH
Group 3
1.0 g/kg MH
Caspase-9,
IHC
+ive control is
human
colon
(a) (b) (c) (d)
Apaf-1,
IHC
+ive control is
human
colon
(a) (b) (c) (d)
P53,
IHC
+ive control is
human breast
cancer
(a) (b) (c) (d)
FASLG,
IHC
+ive control is
human colon
cancer
(a) (b) (c) (d)
FADD,
IHC
+ive control is
human breast
cancer
(a) (b) (c) (d)
IFNGR1,
IHC
+ive control is
human
colon
(a) (b) (c) (d)
lose a lot of weight with worse outcomes [37]. It is hypothe-
sized that TH andMHmight be able to improve body weight
gain.
It has been demonstrated that haematological parame-
ters are correlated with prognosis of cancer [18]. Pre- and
posttreatment studies have shown that breast cancer patients
have abnormal or poor blood parameters [18]. We observed
intriguing findings of blood parameters after the adminis-
tration of TH and MH in the rats bearing breast cancer.
Treatment with similar strengths of TH andMHhad a poten-
tiating effect on the haematological parameters such as RBC,
Hb, PCV, lymphocytes, and eosinophils. These treatments
presented a slight lowering effect on the levels of RDW, poly-
morphs, andmonocytes compared to the nontreated positive
control (Table 7). Research has reported a lower level of RBC,
Hb, MCV, MCH, MCHC, and lymphocytes in pre- and post-
treatment breast cancer patients. Anaemia was also reported
in these patients due to iron deficiency [18, 38]. A higher level
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Table 10: The immunohistochemical expression of antiapoptotic proteins in TH and MH treated tumours compared with the tumours of
nontreated control; (a) +ive control for IHC analysis, (b) +ive control for study (group bearing breast cancer but received no honey treatment),
(c) 1.0 g/kg TH, and (d) 1.0 g/kg MH. All specimens were examined at ×400 microscopic magnification and brown color showed antibody
positivity. Arrows in plates (c) and (d) show lower expression of antiapoptotic proteins in treated tumours compared with the nontreated
control. TNF-𝛼: tumour necrosis factor alpha, COX-2: cyclooxygenase-2, ESR1: estrogen receptor 1, Bcl-xL: B-cell lymphoma extra large, TH:
Tualang honey, and MH: Manuka honey.
Proteins +ive control(for IHC)
Group 1
+ive control
Group 2
1.0 g/kg TH
Group 3
1.0 g/kg MH
TNF-𝛼,
IHC
+ive control is
human breast
cancer
(a) (b) (c) (d)
COX-2,
IHC
+ive control is
human colon
cancer
(a) (b) (c) (d)
ESR1,
IHC
+ive control is
human breast
cancer
(a) (b) (c) (d)
Bcl-xL,
IHC
+ive control is
human tonsils
(a) (b) (c) (d)
of RDW, TWBC, and polymorphs can be observed in breast
cancer patients [18]. There are studies which have reported
conflicting results on platelets count in pretreatment breast
cancer patients [18, 38]. A study reported no relationship
between curability of cancer and basophils, and eosinophils,
and monocytes [18]. Our findings show that TH and MH
may alter or tend to normalize these parameters to ameliorate
carcinogenesis in breast cancer.The findings of our study also
suggest that honeymaymodifyHb, RBC, and PCV to amelio-
rate anaemia. Exclusive honey feeding in the absence of any
disease significantly modifies the haematological parameters
[39].
Apaf-1 is reported as an essential target in the intrinsic
apoptotic pathway to regulate Caspase-9 pathway apoptosis
[20]. Its loss results in tumour cells evading apoptosis [20].
Our data reported that TH and MH cause increase of the
concentration of Apaf-1 at serum level (Table 4). The finding
is validated when we observed a higher expression of this
protein in treated cancer masses as well (Figure 3). Similarly,
TH and MH were found to potentiate the expression of
proapoptotic proteins Caspase-9 and p53. We may postulate
that TH and MH caused upregulation of the expression of
Apaf-1, Caspase-9, and p53 and thusmay activate the intrinsic
apoptotic pathway to promote apoptosis. It is evidenced by
regressed growth patterns and the low histological grad-
ing in treated tumours. The possible mechanism demon-
strates that TH and MH akin to chemotherapeutic agents
may induce apoptosis through multiple signaling pathways
that converge on the mitochondria to cause the release of
cytochrome c. Cytochrome c binds to Apaf-1 in the pres-
ence of dATP/ATP (deoxyadenosine triphosphate/adenosine
triphosphate), which then binds to procaspase-9 to form
a cytochrome c–Apaf-1–Caspase-9 complex, called apop-
tosome. Apoptosome enables enzymatic self-activation of
Caspase-9 that subsequently activates procaspase-3. This
ultimately results in cell death [20].Honeymediates apoptosis
mainly through the intrinsic apoptotic pathway and by
enhancing proapoptotic proteins expression [5, 14]. p53 in
the intrinsic apoptotic pathway exhibits Apaf-1 as an essential
downstream target to regulate apoptosis [20]. A similar find-
ing reports that honey causes increase in p53 expression in
colon cancer in its anticanner effect [40]. We can assume that
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bymodulating p53 expression through the intrinsic apoptotic
pathway with the involvement of Apaf-1 and Caspase-9.
Our findings showed no evidence of the activation of
FASLG and FADD, hence no involvement of Caspase-8 or the
extrinsic apoptotic pathway in TH andMHmediated apopto-
sis. Our results are in line with another study which demon-
strated that Manuka honey induces intrinsic or Caspase-9
apoptotic pathway in breast cancer. This study showed no
evidence of the involvement of Caspase-8 pathway [17].
Investigations on human tumour cells have reported that
the resistance of a variety of tumour cell lines to IFN-𝛾 is
owing to the defects in IFNGR-mediated signaling cascades
[41]. The reduced expression of IFNGR1 is tightly associated
with poor prognosis and more aggressiveness of cancer [41].
This emphasizes the importance of the expression of IFNGR1
in the prevention of cancer. The higher expression of IFNGR
in TH and MH treated cancer tissues is supported by higher
expression of IFN-𝛾 at serum level in our treated groups.
Thus, TH and MH treatments cause a higher expression of
IFN-𝛾 as well as its binding receptor IFNGR1. The results of
our study are supported by a research reporting that honey
may cause high serum levels of IFN-𝛾 which inhibit tumour
formation [42]. Our study provides evidence that Tualang
and Manuka honeys are novel immune potentiators which
induce IFN-𝛾 and IFNGR1 expression to potentiate IFN-𝛾
activities in breast tumour cells.
TNF-𝛼 has been shown to play a dual role, beneficial and
deleterious effect for the promotion or inhibition of infectious
diseases [43]. Investigations strongly suggest that the expres-
sion of TNF-𝛼 in breast tumours actually promotes tumour
growth. The higher expression of TNF-𝛼 in inflammatory
breast carcinoma was found to be associated with increasing
tumour grade and the metastatic behavior of breast carcino-
mas [23]. Our study shows a lower TNF-𝛼 concentration at
serum level as well as a lower expression in tumour specimens
of treated groups, which further validates our results. TNF-𝛼
is produced bymonocytes [44], and our study also shows that
THandMHtreatments cause lowering of themonocytes level
in blood.This validates that TH andMHhinder this signaling
pathway by lowering TNF-𝛼 as well asmonocytes to cause the
anticancer effects. Research has shown that MH stimulates
monocytes to release tumour necrosis factor-alpha [45]
to enhance immune response. But, this study has reported
modulatory effect of honey on TNF-𝛼 in disease-free models,
contrary to cancer models of our study.We can postulate that
TH and MH are anti-TNF-𝛼 agents.
A proinflammatory marker, COX-2, is overexpressed in
breast cancer and might be a crucial therapeutic target
in breast cancer. It leads to the destruction of the basal
membrane and the formation of new blood vessels allowing
tumour growth [24]. Our study suggests that TH and MH
treatment may inhibit COX-2 pathway cell proliferation-
related transcriptional programs in breast carcinomas. This
mechanism is validated by the reduced tumour size in our
treated groups. Honey has been reported to be involved in
regulation of COX-2, as an anti-inflammatory agent [46].
Phenolic acids and polyphenols in honey have been reported
to be responsible for anti-inflammatory activity induced
by COX-2 pathway [46]. It can also be hypothesized that
COX-2 inhibition by TH and MH may cause lower tumour
multiplicity through reduction in inflammation caused by
COX-2.The proposedmechanism bywhich TH andMHmay
inhibit COX-2-induced inflammation in carcinogenesis is
supported by previous findings [46].These findings proposed
that honey may inhibit inflammation through suppression of
NF-𝜅B pathway by blocking this signaling pathway. Thus, it
may be presumed that TH and MH may intervene in this
inflammatory signaling pathway to downregulate the COX-2
expression. COX-2 expression is regulated by TNF-𝛼 and our
study also shows a lower expression of TNF-𝛼. This further
validates the hindering of this inflammatory pathway by TH
and MH.
A study has reported that overexpression of Bcl-xL in
breast cancer patients is associated withmetastasis and worse
prognosis [25].The decrease of Bcl-xL expression observed in
THandMH treated tumours suggests that the administration
of TH and MH can lead to lower tumour cells proliferation
and increased apoptosis. Bcl-xL exerts its effect through the
loss of mitochondrial outer membrane integrity by blocking
both mitochondrial swelling and membrane hyperpolariza-
tion [47]. Our findings suggest that Bcl-xL expression was
hindered by TH andMH at its intrinsic mitochondrial apop-
totic pathway. This ultimately promotes apoptosis through
increased expression of mitochondrial pathway proteins,
Caspase-9, p53, and Apaf-1, as observed in our study. A study
on walker 256 breast carcinoma verified that honey may
modulate the expression of pro- and antiapoptotic proteins in
animal models [34].
The findings of our study show that TH andMH showed a
lowering effect on E2 concentration at serum level (Figure 3)
and ESR1 at cancer tissues level (Tables 8 and 10). Breast can-
cer patients had higher levels of estrogens and ER-mediated
bioactivities [19]. Higher serum level of E2 has been reported
in breast cancer patients [19]. It promotes cell proliferation
and suppresses apoptosis by directly modulating the genes
transcription. Thus, estrogen is considered as an important
target in breast cancer treatment. It has been reported that
treatment with estrogen-lowering drugs shrinks tumours of
breast cancer patients [48]. Thus, TH and MH act as natural
estrogen-lowering drugs and shrink tumour size as reported
in our study.The inhibition of ESR1 may decrease the risk for
hormonal breast cancer [19]. Research has shown that exoge-
nous or synthetic estradiol (E2) can be used as a treatment in
ER positive breast cancer to cope with ER proliferative path-
way and to stimulate the apoptotic pathway [49]. It is also pos-
sible that honey, which is a natural phytoestrogen [7], plays
its role in modulating the endogenous estrogen and estrogen
receptors and may stimulate the apoptotic pathway. Based
on our results, we can hypothesize that TH and MH may
reduce E2 and ESR1 expression to inhibit tumour growth. TH
and MH may bind to the ER, similar to drugs, and may dis-
rupt receptor dimerization by inhibiting cytoplasmic-nuclear
shuttling to block ER nuclear localization. It will bind to
the ERs and therefore prevent its activation by estrogen,
leading to its degradation similar to ERs targeting drugs.
Honey exerts estrogen agonistic effect at high concentrations
(20–100 𝜇g/mL) and antagonistic effect at low concentrations
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(0.2–5𝜇g/mL) [50]. This antiestrogenic effect was attributed
to its flavonoids or polyphenols content [50]. This study
reported in vitro analysis of estrogen receptors only. Our
study reports in vivo analysis of E2 and ESR1 with an
antagonist effect of THandMH. It was also observed thatMH
showed better effects in terms of tumour multiplicity, reduc-
tion, size and weight, and mildness in histological features. It
also showed better results for some markers at haematologi-
cal, serological, and cancer tissues level.This difference in the
efficacy of two honeys may be attributed to their floral origin
and compositional differences. Overall, TH and MH if tested
for antibreast cancer potency, they are akin to manage the
disease through modulation of different pathways involved,
as reported in our results. Studies have elucidated various
classes of active ingredients in honeywhich act synergistically
to bring about the maximum therapeutic efficacy [5], making
honey a novel anticancer agent of great interest.
5. Conclusions
Tualang and Manuka honeys exhibit antibreast cancer activ-
ity. The mechanism by which TH and MH exert cancer-
therapeutic effects is multifold, through modulation of
immune response by ameliorating haematological and sero-
logical parameters and by activation of the intrinsic apop-
totic pathway through upregulation of the expression of
proapoptotic proteins such as Caspase-9, Apfa-1, p53, IFN-𝛾,
and IFNGR1. Concomitantly, these honeys downregulate the
expression of antiapoptotic proteins such as Bcl-xL, TNF-𝛼,
COX-2, E2, and ESR1.We believe that current findings should
facilitate further research to investigate whether TH andMH
could synergize with or be a substitute for chemotherapeutic
drugs given at suboptimal doses for cancer therapy.Themost
reliable study on the usefulness of TH and MH as natural
cancer-therapeutic agent or adjuvant is to conduct research
in more animal and clinical trials.
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